Introduction: Secretory carcinoma (SC) of salivary gland, a recently described entity resembling secretory carcinoma of breast. It harbors a t(12;15) (p13;q25) translocation resulting in a genetic fusion product ETV6-NTRK3, alternative fusion partners like ETV6-RET, ETV6-MAML3, and ETV6-MET also been described in SC cases lacking classic transcript which aids in targeted therapy. It is characterised by strong immunopositivity for S100, mammaglobin and vimentin. Aim: As the clinicopathological and treatment outcome data of SC of head and neck sites is limited, we aimed to address the same in this study. Methodology: After ethical approval of the institutional ethics committee, a through a retrospective search of all salivary gland tumors were made from our electronic medical record. Five cases of SC of head and neck were found, out of which 03 cases involved salivary glands, and 02 cases involved buccal mucosa. Result: The demographic, clinical, histopathological, radiological, treatment and follow up data were aggregated for all patients. Patients age varies from 12- 70 years, with majority occurred in females. All the patients underwent surgical excision and neck was addressed based on clinico-radiological finding, adjuvant therapy in the form of radiotherapy were received in 02 patients in view of higher stage. On average follow up of 06 months, no evidence of disease recurrence noted. Conclusion: SC is a low grade tumor with favorable outcome and prognosis, histomorphological features with IHC is mandatory for diagnosis. Standard of treatment is surgery, adjuvant treatment based on high risk features, with long term observation is needed.
Sarkar et al. (Thu,) studied this question.